Inhibitors of Hepatitis C Virus Polymerase: Synthesis and Biological Characterization of Unsymmetrical Dialkyl-Hydroxynaphthalenoyl-benzothiadiazines
作者:Rolf Wagner、Daniel P. Larson、David W. A. Beno、Todd D. Bosse、John F. Darbyshire、Yi Gao、Bradley D. Gates、Wenping He、Rodger F. Henry、Lisa E. Hernandez、Douglas K. Hutchinson、Wen W. Jiang、Warren M. Kati、Larry L. Klein、Gennadiy Koev、William Kohlbrenner、A. Chris Krueger、Jinrong Liu、Yaya Liu、Michelle A. Long、Clarence J. Maring、Sherie V. Masse、Tim Middleton、Debra A. Montgomery、John K. Pratt、Patricia Stuart、Akhteruzzaman Molla、Dale J. Kempf
DOI:10.1021/jm8010965
日期:2009.3.26
The hepatitis C virus (HCV) NS5B polymerase is essential for viral replication and has been a prime target for drug discovery research. Our efforts directed toward the discovery of HCV polymerase inhibitors resulted in the identification of unsymmetrical dialkyl-hydroxynaphthalenoyl-benzothiadiazines 2 and 3. The most active compound displayed activity in genotypes 1a and 1b polymerase and replicon
丙型肝炎病毒(HCV)NS5B聚合酶对于病毒复制至关重要,并且已成为药物发现研究的主要目标。我们针对发现HCV聚合酶抑制剂的努力导致鉴定出不对称的二烷基-羟基萘二甲酰基-苯并噻二嗪2和3。在基因型1a和1b聚合酶和复制子细胞培养抑制试验中,活性最高的化合物分别在亚纳摩尔浓度和低纳摩尔浓度下显示出活性。它还在大鼠中表现出出色的药代动力学特征,静脉给药后血浆消除半衰期为4.5小时,口服生物利用度为77%,肝脏峰值浓度为21.8μg/ mL。